Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
241 hedge funds and large institutions have $4.96B invested in Intra-Cellular Therapies Inc. in 2022 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 90 increasing their positions, 64 reducing their positions, and 31 closing their positions.
113% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 31
106% more call options, than puts
Call options by funds: $33.7M | Put options by funds: $16.4M
63% more funds holding in top 10
Funds holding in top 10: 8 → 13 (+5)
41% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 64
38% more capital invested
Capital invested by funds: $3.6B → $4.96B (+$1.36B)
16% more funds holding
Funds holding: 208 → 241 (+33)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$211M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$48.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$47.4M |
| 4 |
BlackRock
New York
|
+$38.9M |
| 5 |
Holocene Advisors
New York
|
+$37.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$39.3M |
| 2 |
SC
Samlyn Capital
New York
|
-$32.5M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$24.2M |
| 4 |
Two Sigma Investments
New York
|
-$14.5M |
| 5 |
EP
Eversept Partners
New York
|
-$12.1M |
ITCI Hedge Fund Activity: Q1 2022 in Review
241 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2022, worth a combined $4.96B — up 38% from $3.6B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new ITCI positions and 31 closed out — a net gain of 35 holders — while 90 added to existing stakes and 64 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $211M. The largest seller was Wasatch Advisors, cutting an estimated $39.3M.
- 241 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2022, up from 208 in Q4 2021.
- Funds reported $4.96B of Intra-Cellular Therapies Inc. stock for Q1 2022, up 38% quarter-over-quarter.
- 66 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2022 and 31 closed out, a net change of +35 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q1 2022 was Wellington Management Group, an estimated $211M added.
- The largest Intra-Cellular Therapies Inc. seller in Q1 2022 was Wasatch Advisors, an estimated $39.3M sold.
Based on aggregated 13F filings for Q1 2022.